TaiGen Biotech's Novel Antibiotic Approved for Use in China

TaiGen Biotech, a Taiwan company with a Beijing subsidiary, received CFDA approval to market a novel antibiotic, Taigexyn ® (nemonoxacin), in mainland China. The antibiotic showed activity against drug-resistant bacterial strains. TaiGen said Taigexyn is the first Class 1.1 new drug developed by a Taiwanese company approved for China use and also the first new drug approved after the CFDA required companies to self-inspect clinical trial data in July 2015. In China, Taigexyn will be marketed by Zhejiang Medicine, which in-licensed rights to the antibiotic for $8 million upfront plus royalties and sales milestones. More details.... Stock Symbol: (TWO: 4157) Share this with colleagues: // //